Christopher A. Viehbacher

President and Chief Executive Officer at BIOGEN

Since November 14, 2022

Age

64 years

Education

Earned a Bachelor of Commerce degree from Queen's University in Kingston, Ontario, Canada.

Tenure

Joined BIIB as President and Chief Executive Officer in November 2022, serving also as a member of its Board of Directors.

Also at BIOGEN

GGP

Ginger Gregory, Ph.D.

Executive Vice President and Chief Human Resources Officer

MRM

Michael R. McDonnell

Executive Vice President and Chief Financial Officer (until February 28, 2025)

Nicole Murphy

Executive Vice President, Pharmaceutical Operations and Technology

About

A seasoned executive with a strong international background, he began his career at PricewaterhouseCoopers LLP where he qualified as a chartered accountant and later spent over 20 years at GlaxoSmithKline, holding various roles including the President of its North American pharmaceutical division.

He further refined his leadership capabilities as the Global CEO of Sanofi from 2008 to 2014 and served as Managing Partner at Gurnet Point Capital from 2015 to 2022, experiences that have provided him with deep insights into both large-scale pharmaceutical operations and innovative biotech ventures.

At BIIB, he brought his expansive expertise to the role of President and Chief Executive Officer in November 2022, complementing his strategic vision with active contributions on multiple public company boards and academic boards, such as those of Vedanta Biosciences and Northeastern University.

$BIIB Performance Under Christopher A. Viehbacher

Past Roles

Organization	Role	Date Range	Details
Gurnet Point Capital	Managing Partner	2015 - 2022	Boston-based investment fund role
Sanofi S.A.	Global CEO	2008 - 2014	Focused on creating new revenue sources while addressing loss of exclusivity for its portfolio
GlaxoSmithKline (GSK)	Various roles including President of the North American pharmaceutical division	Over 20 years	Held positions across Germany, Canada, France, and the U.S.
PricewaterhouseCoopers LLP	Early career role / Chartered Accountant	N/A	Began his career and qualified as a chartered accountant
Healthcare Investment Fund	Co-founder	N/A	Contributed to the development of innovative companies

External Roles

Organization	Role	Date Range	Details
Northeastern University	Trustee	N/A	Current position
Stanford Medical School	Member of the Board of Fellows	N/A	Current position

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,600,000	Annual	Fixed base salary for the year 2023
Company Matching Contribution to 401(k) Plan	$19,800	Annual	Matching contribution to 401(k) as per plan
Company Contribution to SSP Account	$72,983	Annual	Contribution to the Supplemental Savings Plan
Value of Company-Paid Life Insurance Premiums	$1,091	Annual	Cost of company-paid life insurance premiums

Performance Compensation

Data from FY 2023

Annual Bonus Plan

Metric	Value	Additional Details
Target Bonus Opportunity	150% of Base Salary	Based on achieving company and individual performance goals
Base Salary for Calculation	$1,600,000	Used as the basis for bonus calculation
Company Multiplier	Range: 0% to 150%	Actual performance at approximately 99% indicated by company results
Individual Multiplier	Range: 0% to 150%	Based on individual performance; actual value here is pegged at 100%
Cap on Combined Multiplier	225% of Target	The combined multiplier cannot exceed this limit
Bonus Award	$2,376,000	Final calculated bonus payout for 2023
Performance Metrics Evaluated	Revenue, EPS, Pipeline, ESG	Revenue achieved at 99.5% & EPS at 99.4% of targets ; plus strategic and operational metrics
Evaluation Period	Calendar Year 2023	Performance assessed for the 2023 fiscal year

_No additional performance compensation such as Long-Term Incentive Awards or Performance-Based Restricted Stock Units were applicable in 2023. _